Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03811431
Other study ID # BIOPTICON
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 1, 2011
Est. completion date January 1, 2020

Study information

Verified date January 2019
Source Iuliu Hatieganu University of Medicine and Pharmacy
Contact Tudor Mocan, MD
Phone +40 799861946
Email Mocac.Tudor@umfcluj.ro
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this study is to compare contrast-enhanced ultrasound guided liver biopsy (CEUS-LB) with conventional ultrasound guided liver biopsy (US-LB) in the diagnosis of liver tumors developed on a background of advanced chronic liver diseases. All patients referred to our department with a CT/MRI diagnosis of hepatic neoplasia will be randomly assigned to either CEUS-LB or US-LB. All LB will be performed by the same investigator. For the randomisation the flip coin technique will be used. One investigator without access to previous C/MRI/US report will do the randomization


Description:

A prospective parallel group clinical trial will be performed. The study protocol was implemented in our Institute starting January 2011 ending January 1 2020. During this period, all patients with a suspicion of primary liver neoplasia either on CT or MRI will be evaluated in different departments from our Institute for possible inclusion. Patients with a typical aspect of benign FLLs will not be included in the study. Patients fulfilling the following criteria: presence of cirrhosis or other chronic liver disease (according to a liver stiffness evaluated by transient elastography higher than 10 kilopascals), Child-Pugh score no higher than B7 and absence of perihepatic ascites, platelet count > 50.000 per mm3 or an international normalized ratio < 1.6; will be further on sent to the department of interventional ultrasound. ). All patients referred to interventional department will underwent a B-mode ultrasound (1 investigator) testing the feasibility of performing liver biopsy. At this time point the conspicuity of the tumors will be recorded into either poorly or not poorly visible. Included patients will be randomly divided by another investigator (T.M.) without access to the previous US, CT or MRI report into two groups: a group that will underwent US guided liver biopsy (USLB) and another one who will underwent CEUS guided liver biopsy (CEUSLB). The randomization will be made based of flip coin technique. The side of the coin (heads-USLB, tails CEUSLB) determined the assignment of each subject. All biopsies will be performed by the same investigator (Z.S.) with an experience of more than 8 years in ultrasound interventions. Patients assigned to USLB or CEUSLB will be blinded. The investigators assessing the outcomes will not be informed about the LB technique used in each patient. The reasons for performing biopsy will be either inconclusive CT/MRI findings , or patients with a typical pattern of HCC on CT/MRI in whom a histological diagnosis is necessary in order to start systemic therapy (sorafenib). Different from other major society's guidelines, in our country a histological diagnosis of HCC is mandatory in patients referred for sorafenib treatment. Patients with small FLLs (BCLC 0 or A) and typical aspect of HCC on CT/MRI will be sent directly to surgery or radiofrequency ablation according to EASL guidelines.


Recruitment information / eligibility

Status Recruiting
Enrollment 138
Est. completion date January 1, 2020
Est. primary completion date January 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- presence of cirrhosis or other chronic liver disease (according to a liver stiffness evaluated by transient elastography higher than 10 kilopascals)

- Child-Pugh score no higher than B7 and absence of perihepatic ascites

- platelet count > 50.000 per mm3

- international normalized ratio < 1.6

Exclusion Criteria:

- tumors located tin sonography blind areas

- refuse to sign the informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Contrast enhanced ultrasound guided liver biopsy
Conventional liver biopsy

Locations

Country Name City State
Romania Regional Institute of Gastroenterology and Hepatology "Octavian Fodor" Cluj-Napoca Please Enter The State Or Province

Sponsors (1)

Lead Sponsor Collaborator
Iuliu Hatieganu University of Medicine and Pharmacy

Country where clinical trial is conducted

Romania, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients in whom contrast enhanced ultrasound guided liver biopsy leads to the final diagnosis as compared to conventional ultrasound guided liver biopsy. The final diagnosis will be assessed based on histological examination. In patients in whom a final histological diagnosis can not be achieved with the use of contrast enhanced or ultrasound guidance a second liver biopsy will be considered if appropriate in the next 3-4 weeks. In cases where a second liver biopsy will be judged not to be necessary a follow-up using imaging techniques will be performed until a final diagnosis is reached. From randomisation until the first documented histological diagnosis. In cases with a negative diagnosis based on histology imaging follow-up using CT or MRI will be carried on for a period of at least 12 months.
See also
  Status Clinical Trial Phase
Recruiting NCT05255042 - Tissue Models for Liver Disease
Completed NCT04473482 - Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Trial N/A
Not yet recruiting NCT05120557 - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH N/A
Completed NCT02917408 - Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
Recruiting NCT03773887 - Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease N/A
Recruiting NCT00345930 - DILIN - Prospective Study
Completed NCT00148031 - Improving Hepatitis C Treatment in Injection Drug Users Phase 4
Terminated NCT00031135 - Total Parenteral Nutrition-Associated Liver Disease Phase 2
Completed NCT00005305 - Hepatitis Delta Infections in Hemophiliacs N/A
Completed NCT00005304 - Delta Hepatitis and Liver Disease in Hemophiliacs
Completed NCT00222664 - Qidong Hepatitis B Intervention Study Phase 4
Recruiting NCT06195917 - Robotic-assisted Percutaneous Transhepatic Puncture N/A
Recruiting NCT04551742 - Social & Contextual Impact on Children Undergoing Liver Transplantation
Completed NCT04782050 - Non-invasive Ultrasound Diagnosis of Chronic Liver Diseases in Hepatology Consultation N/A
Completed NCT03614039 - Effect of Probiotic and Smectite Gel on NAFLD N/A
Recruiting NCT04518852 - TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC Phase 2
Recruiting NCT05499585 - Treating Pediatric NAFLD With Nutrition N/A
Terminated NCT03396705 - Liver Regeneration
Completed NCT04341012 - Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases
Recruiting NCT05733832 - A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease N/A